{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-22-044662","form_type":"8-K","ticker":"TECX","cik":"0001681087","company_name":"Tectonic Therapeutic, Inc.","filed_at":"2022-12-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.694553+00:00","generated_at":"2026-06-21T08:10:14.690580+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"AVROBIO reports positive clinical data for Gaucher gene therapy; plans Phase 2/3 trial for GD3 in H2 2023","bullets":["GD3 pediatric patient (age 11) shows normalized GCase enzyme and biomarker; remains off ERT/SRT 15 months post AVR-RD-02; no new neurological signs.","Four GD1 patients: liver volume reduced up to 24%, spleen up to 23%; lyso-Gb1 decreased 21%-70% below ERT baseline.","AVROBIO plans global, randomized Phase 2/3 trial for GD3 in H2 2023, ~40 patients, 1:1 gene therapy vs. ERT, following FDA/MHRA feedback.","No drug-related AEs; all AEs related to conditioning or underlying disease, mostly mild/moderate.","plato platform late-stage ready; no major CMC changes anticipated for late-stage trials."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-22-044662","json":"https://secwatch.observer/filing/0001140361-22-044662.json","markdown":"https://secwatch.observer/filing/0001140361-22-044662.md","text":"https://secwatch.observer/filing/0001140361-22-044662.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1681087/000114036122044662/0001140361-22-044662-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1681087/000114036122044662/ny20005640x4_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T08:10:14.690580+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}